Robust isolation of malignant plasma cells in multiple myeloma.

Summary, in English

Molecular characterization of malignant plasma cells is increasingly important for diagnostic and therapeutic stratification in multiple myeloma (MM). However, the malignant plasma cells represent a relatively small subset of bone marrow cells, and need to be enriched prior to analysis. Currently, the cell surface marker CD138 (SDC1) is used for this enrichment, but has an important limitation in that its expression decreases rapidly after sampling. Seeking alternatives to CD138, we performed a computational screen for myeloma plasma cell markers and evaluated seven candidates systematically. Our results conclusively show that the markers CD319 (SLAMF7/CS1) and CD269 (TNFRSF17/BCMA) are considerably more robust than CD138, and enable isolation of myeloma plasma cells under more diverse conditions, including in samples that have been delayed or frozen. Our results form the basis of improved procedures for characterizing cases of multiple myeloma in clinical practice.

• Author: Ildiko Frigyesi; Jörgen Adolfsson; Mina Ali; Mikael Kronborg Christophersen; Ellinor Johnsson; Ingemar Turesson; Urban Gullberg; Markus Hansson; Björn Nilsson
• Department/s: Hematogenomics; Myeloma research group; Division of Hematology and Transfusion Medicine; Division of Clinical Genetics; Department of Clinical Sciences, Malmö; BioCARE: Biomarkers in Cancer Medicine improving Health Care, Education and Innovation
• Publishing year: 2014
• Language: English
• Pages: 1336-1340
• Publication/Series: Blood
• Volume: 123
• Issue: 9
• Links: http://www.ncbi.nlm.nih.gov/pubmed/24385542?dopt=Abstract; http://dx.doi.org/10.1182/blood-2013-09-529800
• Document type: Journal article
• Publisher: American Society of Hematology
• Topic: Hematology
• Status: Published
• Project: Genetic predisposition for multiple myeloma
• Research group: Hematogenomics; Myeloma research group
• ISBN/ISSN/Other: ISSN: 1528-0020